✦ LIBER ✦

Prospective investigation of risk factors for gastrointestinal adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study

✍ Scribed by R. Burger; M. Brady; M. Bookman; B. Monk; J. Walker; H. Homesley; J. Fowler; B. Greer; M. Boente; S. Liang

Book ID: 113962737
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 55 KB
Volume: 120
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2010.12.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial of Bevacizumab in Persist

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

✍ Burger, R. A.; Sill, M. W.; Monk, B. J.; Greer, B. E.; Sorosky, J. I. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 112 KB

Independent radiologic review of the Gyn

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer

✍ Burger, Robert. A.; Brady, Mark F.; Rhee, Joon; Sovak, Mika A.; Kong, George; Ng 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 393 KB

Paclitaxel poliglumex and carboplatin as

Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncology Group

✍ Mark A. Morgan; Kathleen M. Darcy; Peter G. Rose; Koen DeGeest; Michael A. Bookm 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 164 KB

OCEANS: A Randomized, Double-Blind, Plac

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

✍ Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Hus 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 348 KB

A phase II trial of intraperitoneal EGEN

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Alvarez, Ronald D.; Sill, Michael W.; Davidson, Susan A.; Muller, Carolyn Y.; Be 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 308 KB

Randomized phase III trial of tamoxifen

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

✍ Jean A. Hurteau; Mark F. Brady; Kathleen M. Darcy; William P. McGuire; Pamela Ed 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 490 KB